Management of Acquired Factor X Deficiency Caused by In Vitro Non-neutralizing Anti-factor X Autoantibodies with Pre-emptive Corticosteroid Therapy.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
2023
Historique:
medline: 18 8 2023
pubmed: 17 8 2023
entrez: 16 8 2023
Statut: ppublish

Résumé

Coagulation factor X (FX) deficiency causes severe hemorrhagic symptoms. We herein report a 90-year-old man with hemorrhagic symptoms and prolongation of prothrombin time (PT) and activated partial thromboplastin time (APTT). Cross-mixing tests showed a factor deficiency pattern, but administration of plasma products was not effective. Acquired coagulation factor deficiency was suspected, and immunosuppressive therapy was started. After the intervention, his hemorrhagic symptoms improved. A decrease in FX activity was later confirmed, and anti-FX autoantibody was retrospectively detected by an enzyme-linked immunosorbent assay. Immediate intervention is important for patients suspected of having acquired coagulation factor deficiency.

Identifiants

pubmed: 37587057
doi: 10.2169/internalmedicine.0849-22
pmc: PMC10484778
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Autoantibodies 0
Blood Coagulation Factors 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2401-2406

Références

Clin Case Rep. 2015 Jul;3(7):587-93
pubmed: 26273448
Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):116-20
pubmed: 24074948
Intern Med. 2020 May 15;59(10):1303-1308
pubmed: 32023586
Blood. 2001 Mar 15;97(6):1885-7
pubmed: 11238135
Semin Thromb Hemost. 2022 Mar;48(2):206-218
pubmed: 34942668
Thromb Haemost. 2022 Mar;122(3):320-328
pubmed: 33930902
Haemophilia. 2019 Mar;25(2):e106-e109
pubmed: 30570186
Ann Hematol. 2013 Oct;92(10):1437-8
pubmed: 23463452
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):80-87
pubmed: 31808848
Acta Haematol. 2013;129(1):40-4
pubmed: 23107910
Haemophilia. 2012 Sep;18(5):655-63
pubmed: 23437437
Blood Rev. 2017 Jan;31(1):37-45
pubmed: 27542511

Auteurs

Akio Onishi (A)

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.

Yuji Shimura (Y)

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
Department of Blood Transfusion, Kyoto Prefectural University of Medicine, Japan.

Takahisa Nakamura (T)

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.

Masayoshi Souri (M)

Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Japan.
The Japanese Collaborative Research Group on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare, Japan.

Tsukasa Osaki (T)

Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Japan.
The Japanese Collaborative Research Group on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare, Japan.

Shinsuke Mizutani (S)

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.

Taku Tsukamoto (T)

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.

Tsutomu Kobayashi (T)

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.

Akitada Ichinose (A)

Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Japan.
The Japanese Collaborative Research Group on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare, Japan.

Junya Kuroda (J)

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH